{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:10:00Z","timestamp":1793830200339,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Funding Project of Wenzhou Technology Bureau Research funds in Zhejiang Province","award":["Y20110204"],"award-info":[{"award-number":["Y20110204"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.biopha.2018.05.077","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T08:33:03Z","timestamp":1527582783000},"page":"763-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met\/AKT\/mTOR signaling pathway"],"prefix":"10.1016","volume":"104","author":[{"given":"Chunxiu","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.05.077_bib0005","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2018.05.077_bib0010","first-page":"15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2018.05.077_bib0015","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2018.05.077_bib0020","doi-asserted-by":"crossref","first-page":"15031","DOI":"10.1007\/s13277-016-5391-5","article-title":"Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression","volume":"37","author":"Xie","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.05.077_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.05.077_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cell.2013.03.019","article-title":"Noncoding RNAs and cancer","volume":"153","author":"Lieberman","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.05.077_bib0040","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ajpath.2013.01.039","article-title":"miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin alpha5 expression","volume":"182","author":"Ohyagi-Hara","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0045","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s12035-014-8822-6","article-title":"MicroRNAs as potential biomarkers for diagnosing cancers of Central nervous system: a meta-analysis","volume":"51","author":"Wei","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2005.06.036","article-title":"miRNAs, cancer, and stem cell division","volume":"122","author":"Croce","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.05.077_bib0055","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/0008-5472.CAN-07-1936","article-title":"MicroRNA signatures in human ovarian cancer","volume":"67","author":"Iorio","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2018.05.077_bib0060","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-07-1731","article-title":"MicroRNA expression profiles in serous ovarian carcinoma","volume":"14","author":"Nam","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2018.05.077_bib0065","doi-asserted-by":"crossref","first-page":"e2436","DOI":"10.1371\/journal.pone.0002436","article-title":"MicroRNA expression and identification of putative miRNA targets in ovarian cancer","volume":"3","author":"Dahiya","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.05.077_bib0070","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1073\/pnas.0801615105","article-title":"Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2018.05.077_bib0075","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1172\/JCI62656","article-title":"microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.05.077_bib0080","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.12659\/MSM.897909","article-title":"MiR-206 attenuates denervation-induced skeletal muscle atrophy in rats through regulation of satellite cell differentiation via TGF-beta1, Smad3, and HDAC4 signaling","volume":"22","author":"Huang","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.biopha.2018.05.077_bib0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7150\/ijbs.10921","article-title":"MiR-206, a key modulator of skeletal muscle development and disease","volume":"11","author":"Ma","year":"2015","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2018.05.077_bib0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/pcmr.12200","article-title":"MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D","volume":"27","author":"Georgantas","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.biopha.2018.05.077_bib0095","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3892\/mmr.2014.2021","article-title":"microRNA-206 overexpression inhibits cellular proliferation and invasion of estrogen receptor alpha-positive ovarian cancer cells","volume":"9","author":"Li","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2018.05.077_bib0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3892\/ijmm.2014.1800","article-title":"MicroRNA-206 overexpression promotes apoptosis, induces cell cycle arrest and inhibits the migration of human hepatocellular carcinoma HepG2 cells","volume":"34","author":"Liu","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2018.05.077_bib0105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3892\/ijo.2014.2802","article-title":"Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma","volume":"46","author":"Mataki","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0110","first-page":"1302","article-title":"MicroRNA-206, down-regulated in hepatocellular carcinoma, suppresses cell proliferation and promotes apoptosis","volume":"61","author":"Yunqiao","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.biopha.2018.05.077_bib0115","article-title":"MicroRNA-206: effective inhibition of gastric cancer progression through the c-Met pathway","volume":"10","author":"Zheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.05.077_bib0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00432-015-2053-8","article-title":"MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2","volume":"142","author":"Ren","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0125","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3892\/or.2015.3731","article-title":"MicroRNA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH3 in colorectal cancer","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2018.05.077_bib0130","doi-asserted-by":"crossref","first-page":"25533","DOI":"10.18632\/oncotarget.4575","article-title":"Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation","volume":"6","author":"Sun","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2018.05.077_bib0135","first-page":"9107","article-title":"miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2018.05.077_bib0140","first-page":"2091","article-title":"Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43","volume":"19","author":"Fu","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2018.05.077_bib0145","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bbrc.2015.06.068","article-title":"Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting","volume":"463","author":"Ge","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2018.05.077_bib0150","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.molonc.2014.07.006","article-title":"miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer","volume":"8","author":"Wang","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0155","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2014.26","article-title":"Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers","volume":"3","author":"Elliman","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.biopha.2018.05.077_bib0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40291-016-0201-8","article-title":"The therapeutic potential of targeting the HGF\/cMET axis in ovarian cancer","volume":"20","author":"Moran-Jones","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.biopha.2018.05.077_bib0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/156652408785747933","article-title":"HGF\/MET signaling in ovarian cancer","volume":"8","author":"Zhou","year":"2008","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.biopha.2018.05.077_bib0170","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tranon.2016.08.011","article-title":"Activity of pan-class I isoform PI3K\/mTOR Inhibitor PF-05212384 in combination with crizotinib in ovarian cancer xenografts and PDX","volume":"9","author":"Iezzi","year":"2016","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2018.05.077_bib0175","first-page":"1109","article-title":"MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met","volume":"20","author":"Li","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2018.05.077_bib0180","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.bmc.2016.03.061","article-title":"Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2","volume":"24","author":"Qiang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2018.05.077_bib0185","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1172\/JCI84876","article-title":"c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma","volume":"126","author":"Huang","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.05.077_bib0190","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.3390\/ijms14048213","article-title":"The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer","volume":"14","author":"Dobbin","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2018.05.077_bib0195","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"23","author":"Altomare","year":"2004","journal-title":"Oncogene"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218326076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218326076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:35:45Z","timestamp":1760096145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218326076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":39,"alternative-id":["S0753332218326076"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.05.077","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met\/AKT\/mTOR signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.05.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}